Literature DB >> 9796369

Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

M Laruelle1.   

Abstract

Over the last ten years, several positron emission tomography (PET) and single photon computerized tomography (SPECT) studies of the dopamine (DA) system in patients with schizophrenia were performed to test the hypothesis that DA hyperactivity is associated with this illness. In this paper, we reviewed the results of fifteen brain imaging studies comparing indices of DA function in drug naive or drug free patients with schizophrenia and healthy controls: thirteen studies included measurement of DA D2 receptors density, two studies compared amphetamine-induced DA release, and two studies measured DOPA decarboxylase activity, an enzyme involved in DA synthesis. We conducted a meta-analysis of the studies measuring D2 receptor density parameters, under the assumption that all tracers labeled the same population of D2 receptors. This analysis revealed that, compared to healthy controls, patients with schizophrenia present a significant but mild elevation of D2 receptor density parameters and a significant larger variability of these indices. We found no statistical evidence that studies performed with radiolabeled butyrophenones detected a larger increase in D2 receptor density parameters than studies performed with other radioligands, such as benzamides. Studies of presynaptic activity revealed an increase in DA transmission response to amphetamine challenge, and an increase in DOPA decarboxylase activity. Together, these data are compatible with both pre- and post-synaptic alterations of DA transmission in schizophrenia. Future studies should aim at a better characterization of these alterations, and at defining their role in the pathophysiology of the illness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796369

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  90 in total

Review 1.  New insights on the neuroanatomy of schizophrenia.

Authors:  G D Pearlson
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

2.  Increased baseline occupancy of D2 receptors by dopamine in schizophrenia.

Authors:  A Abi-Dargham; J Rodenhiser; D Printz; Y Zea-Ponce; R Gil; L S Kegeles; R Weiss; T B Cooper; J J Mann; R L Van Heertum; J M Gorman; M Laruelle
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 3.  Animal models of schizophrenia: a critical review.

Authors:  E R Marcotte; D M Pearson; L K Srivastava
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

Review 4.  Is rational antipsychotic polytherapy feasible? A selective review.

Authors:  Rune Andreas Kroken; Erik Johnsen
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

5.  DRD2/AKT1 interaction on D2 c-AMP independent signaling, attentional processing, and response to olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Francesco Napolitano; Gianluca Ursini; Paolo Taurisano; Raffaella Romano; Grazia Caforio; Leonardo Fazio; Barbara Gelao; Annabella Di Giorgio; Luisa Iacovelli; Lorenzo Sinibaldi; Teresa Popolizio; Alessandro Usiello; Alessandro Bertolino
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

6.  Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Authors:  Jeroen P Koning; Jelle Vehof; Huibert Burger; Bob Wilffert; Asmar Al Hadithy; Behrooz Alizadeh; Peter N van Harten; Harold Snieder
Journal:  Psychopharmacology (Berl)       Date:  2011-07-13       Impact factor: 4.530

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

8.  The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations.

Authors:  Ingo Vernaleken; Lisa Peters; Mardjan Raptis; Robert Lin; Hans-Georg Buchholz; Yun Zhou; Oliver Winz; Frank Rösch; Peter Bartenstein; Dean F Wong; Wolfgang M Schäfer; Gerhard Gründer
Journal:  J Cereb Blood Flow Metab       Date:  2011-05-18       Impact factor: 6.200

9.  Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.

Authors:  Francesca Managò; Maddalena Mereu; Surjeet Mastwal; Rosa Mastrogiacomo; Diego Scheggia; Marco Emanuele; Maria A De Luca; Daniel R Weinberger; Kuan Hong Wang; Francesco Papaleo
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

10.  Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.

Authors:  Alessandro Bertolino; Leonardo Fazio; Grazia Caforio; Giuseppe Blasi; Antonio Rampino; Raffaella Romano; Annabella Di Giorgio; Paolo Taurisano; Audrey Papp; Julia Pinsonneault; Danxin Wang; Marcello Nardini; Teresa Popolizio; Wolfgang Sadee
Journal:  Brain       Date:  2008-10-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.